In this latest podcast Jackie Hunter, Director at BenevolentAI, is interviewed by Vox Markets discussing the fundamentals of AI application within drug development.
AI enables scientists to be their most productive, and the scope of AI application for healthcare today is huge. During this podcast, Jackie sheds light on where she believes some of the critical areas are where we can create impact.
In the broader healthcare system, AI is only beginning to scratch the surface of the value it can create and there are already a range of proof points across the spectrum from radiology, pathology or patient stratification showing how it can help deliver diagnostics much more rapidly and increase efficiencies.
In drug development, the pharmaceutical industry has been slower to adopt AI technology and it is only now that the industry is realising the potential AI can have. For example, one great impact AI can create is in early drug discovery, more specifically in target identification where the process has not evolved for a good fifty years. AI can also help identify better biomarkers and ways in which we can assess how the drug will behave in clinical trials.
Embedding AI in the drug development process will help improve the way drugs are brought to market.
Back to blog post and videos
